Skip to main content

Table 1 Number of Salmonella isolates from pigs collected through the Spanish Veterinary Antimicrobial Resistance Surveillance Network programme that were tested for susceptibility to each of the eleven antimicrobials from 2001 to 2017

From: Patterns of antimicrobial resistance in Salmonella isolates from fattening pigs in Spain

year

TET a,b

CHL a,b

CIP a,b

NAL a,b

GEN a,b

FFC a

CTX a,b

SMX b

AMP b

TMP b

CAZ b

Total count

R c (%)

S d

R (%)

S

R (%)

S

R (%)

S

R (%)

S

R (%)

S

R (%)

S

R (%)

S

R (%)

S

R (%)

S

R (%)

S

 

2001

69 (94.5%)

4

26 (35.6%)

47

13 (17.8%)

60

11 (15.1%)

62

14 (19.2%)

59

5 (6.8%)

68

2 (2.7%)

71

-

0

-

0

-

0

-

0

73

2002

44 (97.8%)

1

15 (33.3%)

30

4 (8.9%)

41

3 (6.7%)

42

2 (4.4%)

43

3 (6.7%)

42

2 (4.4%)

43

-

0

-

0

-

0

-

0

45

2003

72 (84.7%)

13

26 (30.6%)

59

4 (4.7%)

81

3 (3.5%)

82

9 (10.6%)

76

2 (2.4%)

83

5 (5.9%)

80

-

0

-

0

-

0

-

0

85

2004

99 (81.8%)

22

34 (28.1%)

87

9 (7.4%)

112

7 (5.8%)

114

7 (5.8%)

114

10 (8.3%)

111

0 (0%)

121

-

0

-

0

-

0

-

0

121

2005

94 (73.4%)

34

21 (16.4%)

107

10 (7.8%)

118

8 (6.2%)

120

10 (7.8%)

118

2 (1.6%)

126

2 (1.6%)

126

-

0

-

0

-

0

-

0

128

2006

96 (92.3%)

8

33 (31.7%)

71

5 (4.8%)

99

4 (3.8%)

100

2 (1.9%)

102

10 (9.6%)

94

0 (0%)

104

-

0

-

0

-

0

-

0

104

2007

70 (85.4%)

12

24 (29.3%)

58

19 (23.2%)

63

17 (20.7%)

65

5 (6.1%)

77

5 (6.1%)

77

1 (1.2%)

81

-

0

-

0

-

0

-

0

82

2008

42 (63.6%)

24

17 (25.8%)

49

5 (7.6%)

61

4 (6.1%)

62

1 (1.5%)

64

6 (9.1%)

59

0 (0%)

66

37 (56.1%)

29

21 (31.8%)

45

17 (25.8%)

49

0 (0%)

66

66e

2009

177 (83.9%)

34

45 (21.3%)

166

21 (10%)

190

17 (8.1%)

194

11 (5.2%)

200

11 (5.2%)

200

3 (1.4%)

208

133 (63.0%)

78

103 (48.8%)

108

55 (26.1%)

156

0 (0%)

211

211

2010

31 (77.5%)

9

6 (15.0%)

34

8 (20.0%)

32

6 (15.0%)

34

1 (2.5%)

39

2 (5.0%)

38

0 (0%)

40

25 (62.5%)

15

23 (57.5%)

17

6 (15.0%)

34

0 (0%)

40

40

2011

63 (76.8%)

19

14 (17.1%)

68

14 (17.1%)

68

11 (13.4%)

71

3 (3.7%)

79

3 (3.7%)

79

2 (2.4%)

80

48 (58.5%)

33

40 (48.8%)

42

15 (18.3%)

67

1 (1.2%)

81

82

2012

43 (89.6%)

5

7 (14.6%)

41

10 (20.8%)

38

8 (16.7%)

40

5 (10.4%)

43

1 (2.1%)

47

3 (6.2%)

45

26 (54.2%)

22

28 (58.3%)

20

13 (27.1%)

35

1 (2.1%)

47

48

2013

54 (78.3%)

15

8 (11.6%)

61

9 (13.0%)

60

4 (5.8%)

65

5 (7.2%)

64

1 (1.4%)

68

1 (1.4%)

68

40 (58.0%)

29

40 (58.0%)

29

19 (27.5%)

50

0 (0%)

69

69

2017

123 (75.0%)

41

35 (21.3%)

129

34 (20.7%)

130

21 (12.8%)

143

16 (9.8%)

148

-

0

2 (1.2%)

162

118 (72.0%)

46

110 (67.1%)

54

59 (36.0%)

105

1 (0.6%)

163

164

Total

1077 (81.7%)

241

331 (23.6%)

1007

165 (12.5%)

1153

124 (9.4%)

1194

91 (6.9%)

1226

61 (5.3%)

1092

23 (1.7%)

1295

427 (62.8%)

252

365 (53.7%)

315

184 (27.1%)

496

3 (0.4%)

667

1318

  1. aIn the dataset (D_am7) that included the antimicrobial susceptibility testing results for seven antimicrobials from 2001 to 2013
  2. bIn the dataset (D_am10) that contained the antimicrobial susceptibility testing results for 10 antimicrobials from 2008 to 2013 and 2017
  3. cResistant
  4. dSusceptible
  5. eFrom the data of 2008, one isolate had no information about the testing result of GEN, and one had no information about the testing result of FFC
  6. TET tetracycline, CHL chloramphenicol, CIP ciprofloxacin, NAL nalidixic acid, GEN gentamicin, FFC florfenicol, CTX cefotaxime, SMX sulfamethoxazole, AMP ampicillin, TMP trimethoprim, CAZ ceftazidime
Back to article page

BMC Veterinary Research

ISSN: 1746-6148

Contact us